LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
// Eliza Vakana 1, * , Susan Pratt 1, * , Wayne Blosser 1 , Michele Dowless 1 , Nicholas Simpson 2 , Xiu-Juan Yuan 3 , Susan Jaken 3 , Jason Manro 4 , Jennifer Stephens 1 , Youyan Zhang 1 , Lysiane Huber 1 , Sheng-Bin Peng 1 , Louis F. Stancato 1 1 Oncology Discovery Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA 2 Discovery Research, Advanced Testing Laboratory, Cincinnati, OH 45242, USA 3 Cell Technologies, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA 4 Discovery Statistics, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA * These authors contributed equally to this work Correspondence to: Louis F. Stancato, email: stancato_louis@lilly.com Keywords: RAS, RAF, signaling pathways, colorectal cancer, xenograft models Received: September 28, 2016 Accepted: December 13, 2016 Published: December 16, 2016 ABSTRACT Activating mutations in the KRAS and BRAF genes, leading to hyperactivation of the RAS/RAF/MAPK oncogenic signaling cascade, are common in patients with colorectal cancer (CRC). While selective BRAF inhibitors are efficacious in BRAF mut melanoma, they have limited efficacy in BRAF mut CRC patients. In a RAS mut background, selective BRAF inhibitors are contraindicated due to paradoxical activation of the MAPK pathway through potentiation of CRAF kinase activity. A way to overcome such paradoxical activation is through concurrent inhibition of the kinase activity of both RAF isoforms. Here, we further examined the effects of LY3009120, a panRAF and RAF dimer inhibitor, in human models of CRC with various mutational backgrounds. We demonstrate that LY3009120 induced anti-proliferative effects in BRAF mut and KRAS mut CRC cell lines through G1-cell cycle arrest. The anti-proliferative effects of LY3009120 in KRAS mut CRC cell lines phenocopied molecular inhibition of RAF isoforms by simultaneous siRNA-mediated knockdown of ARAF , BRAF and CRAF . Additionally, LY3009120 displayed significant activity in in vivo BRAF mut and KRAS mut CRC xenograft models. Examination of potential resistance to LY3009120 demonstrated RAF-independent ERK and AKT activation in the KRAS mut CRC cell line HCT 116. These findings describe the preclinical activity of a panRAF inhibitor in a BRAF mut and KRAS mut CRC setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 2×
“com/oncotarget with additional evidence that RAS mutations result in resistance to anti-EGFR therapy [4].”
BackgroundThe Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 1×
“As RAF inhibitors, including LY3009120, have been reported to induce RAF dimerization in RASmut settings [15, 17, 42], the phosphorylation event associated with a mobility shift of BRAF could be implicated in dimer dynamics.”
BackgroundCorcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
The RSK family of kinases: emerging roles in cellular signalling
Anjum, R., & Blenis, J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2509 · Cited by 777 · cited 1×
“The activity of p27, a known regulator of G1-progession, is negatively regulated by the MAPK pathway [32] and therefore we examined the effects of LY3009120 on p27 levels.”
BackgroundPhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · cited 1×
“Additionally, a phase II pilot study of vemurafenib in CRC patients with BRAFmut disease also concluded that the selective BRAF inhibitor had limited efficacy in this subset of CRC patients [12].”
BackgroundRichman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., & Quirke, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4295 · Cited by 560
Cited by
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482
“In a preclinical setting, LY3009120 displayed an anti-proliferative effect in KRAS-mutant CRC cell lines and inhibited tumor growth in KRAS-mutant xenograft models [102].”
BackgroundTherapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01541 · Cited by 401
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
“Promising data from in vitro and mouse models 65,68,121–123 led to a phase I clinical trial of LY3009120; however, this study was terminated owing to high toxicity, limited clinical activity (SD as best response in eight of 51 patients) and a lack of major effects on pharmacodynamic markers 124 .”
Metadata
- Authors
- Vakana, E., Pratt, S., Blosser, W., Dowless, M., Simpson, N., Yuan, X.-J., Jaken, S., Manro, J., Stephens, J., Zhang, Y., Huber, L., Peng, S.-B., & Stancato, L. F.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-12-16
- Volume
- 8
- Issue
- 6
- Pages
- 9251-9266
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2567259523
- Cited by
- 70
- References
- 23
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. https://app.cochat.ai/papers/10.18632/oncotarget.14002
- The paper
- Vakana, E., Pratt, S., Blosser, W., Dowless, M., Simpson, N., Yuan, X.-J., Jaken, S., Manro, J., Stephens, J., Zhang, Y., Huber, L., Peng, S.-B., & Stancato, L. F. (2017). LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.14002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.